VistaGen Therapeutics, Inc. (VTGN)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
VistaGen Therapeutics, Inc. (VTGN) trades at $0.24 with AI Score 19/100 (Grade F). VistaGen Therapeutics, Inc. Market cap: $7.94M, Sector: Healthcare.
Price live · AI analysis from May 10, 2026Analyst Coverage for VTGN: VTGN does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates VTGN against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
VTGN: 3/7 perspectives are bullish. Dominant signal: Ray Dalio bullish.
How is this calculated? →VistaGen Therapeutics, Inc. (VTGN) Healthcare & Pipeline Overview
VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in developing and commercializing innovative medicines for central nervous system (CNS) disorders. Their pipeline focuses on addressing significant unmet needs in anxiety, depression, and other CNS conditions, utilizing novel neuroactive nasal sprays and oral N-methyl-D-aspartate receptor antagonists.
What Is the Investment Thesis for VTGN?
VistaGen Therapeutics presents a focused investment opportunity within the CNS therapeutics space. The company's lead candidate, PH94B, targeting the acute treatment of social anxiety disorder, is in Phase III development, representing a near-term catalyst. Positive results from ongoing trials could significantly increase the company's valuation. PH10, in Phase 2B development for MDD, offers a longer-term growth opportunity. The company's gross margin stands at 54.7%. However, the company's negative profit margin of -8486.8% indicates substantial ongoing R&D expenses. Success in clinical trials and eventual commercialization are critical for realizing shareholder value. The company's small market capitalization of $7.94M reflects both the potential upside and the inherent risks associated with clinical-stage biopharmaceutical companies.
Based on FMP financials and quantitative analysis
VTGN Key Highlights
- PH94B is in Phase III development for acute treatment of anxiety in adults with social anxiety disorder, representing a near-term potential catalyst.
- PH10 is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD), offering a longer-term growth opportunity.
- AV-101 is in development as a potential treatment for levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation, expanding the company's therapeutic focus.
- Gross margin of 54.7% indicates potential for profitability upon successful commercialization of drug candidates.
- Market capitalization of $7.94M reflects the high-risk, high-reward nature of investing in a clinical-stage biopharmaceutical company.
Who Are VTGN's Competitors?
VTGN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ALKS Alkermes plc | $54.65 | +0.13% | $9.11B | 51 |
| LLY Eli Lilly and Company | $1202.56 | -0.94% | $1.13T | 98 |
| ABBV AbbVie Inc. | $255.67 | -2.07% | $451.72B | 78 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are VTGN's Key Strengths?
- Novel drug delivery technology (nasal spray)
- Pipeline focused on significant unmet needs in CNS disorders
- Partnerships with established pharmaceutical companies
- Phase III asset for acute anxiety
What Are VTGN's Weaknesses?
- Clinical-stage company with no currently marketed products
- High cash burn rate
- Reliance on successful clinical trial outcomes
- Small market capitalization
What Could Drive VTGN Stock Higher?
- Phase III clinical trial results for PH94B in social anxiety disorder.
- Initiation of Phase 2B clinical trial for PH10 in major depressive disorder.
- Continued development of AV-101 for levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation.
What Are the Key Risks for VTGN?
- Financial-distress signal — its Altman Z-Score of -17.28 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Failure to achieve positive results in clinical trials.
- Regulatory delays or rejection of drug candidates.
- Competition from other pharmaceutical companies in the CNS market.
- Dependence on securing additional funding to support research and development.
- Intellectual property challenges or patent infringement claims.
What Are the Growth Opportunities for VTGN?
- Expansion of PH94B into additional anxiety disorders: Beyond social anxiety disorder, PH94B has the potential to treat a range of other anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, and panic disorders. Each of these indications represents a significant market opportunity, with millions of individuals affected worldwide. Successful clinical trials and regulatory approvals for these additional indications could substantially increase the commercial potential of PH94B. The timeline for this expansion depends on the progress of ongoing and planned clinical trials.
- Advancement of PH10 for Major Depressive Disorder (MDD): PH10, a rapid-onset neuroactive nasal spray, is in preparation for Phase 2B clinical development as a stand-alone treatment for MDD. The MDD market is a large and growing market, with a significant unmet need for more effective and faster-acting treatments. Positive results from Phase 2B trials could lead to further clinical development and eventual commercialization, representing a substantial growth opportunity for VistaGen. The timeline for this opportunity depends on the initiation and completion of the Phase 2B trial and subsequent clinical development stages.
- Development of AV-101 for multiple CNS indications: VistaGen is developing AV-101, an oral N-methyl-D-aspartate (NMDA) receptor antagonist, in combination with oral probenecid, as a potential treatment for levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. Each of these indications represents a significant market opportunity. Successful clinical development and regulatory approval for one or more of these indications could significantly increase the company's value. The timeline for this opportunity depends on the progress of ongoing and planned clinical trials.
- Partnerships and collaborations: VistaGen has established partnerships and collaborations with companies such as Cato Research Ltd., Pherin Pharmaceuticals, Inc., and EverInsight Therapeutics Inc. These collaborations provide access to additional resources, expertise, and funding, which can accelerate the development and commercialization of the company's drug candidates. Future partnerships and collaborations could further enhance the company's growth prospects. The specific impact of these partnerships will depend on the terms and success of each collaboration.
- Geographic expansion: VistaGen has the potential to expand its geographic reach beyond the United States. The company's collaboration with EverInsight Therapeutics Inc. focuses on the development and commercialization of PH94B and PH10 in Greater China, South Korea, and Southeast Asia. Expanding into other geographic markets could further increase the company's revenue and growth potential. The timeline for geographic expansion will depend on regulatory approvals and commercialization strategies in each target market.
What Opportunities Does VTGN Have?
- Expansion of PH94B into additional anxiety disorders
- Advancement of PH10 for MDD
- Development of AV-101 for multiple CNS indications
- Potential for breakthrough therapy designations and accelerated approvals
What Threats Does VTGN Face?
- Failure to achieve positive clinical trial results
- Regulatory setbacks
- Competition from established pharmaceutical companies
- Difficulty raising additional capital
What Are VTGN's Competitive Advantages?
- Proprietary neuroactive nasal spray technology for rapid-onset treatment.
- Patent protection for its drug candidates.
- Clinical data supporting the safety and efficacy of its drug candidates.
- Established collaborations with other companies in the pharmaceutical industry.
What Does VTGN Do?
VistaGen Therapeutics, Inc., founded in 1998 and headquartered in South San Francisco, California, is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative medicines for central nervous system (CNS) disorders. The company's primary focus is on addressing unmet needs in anxiety, depression, and other CNS conditions. VistaGen's pipeline features several promising drug candidates, including PH94B, a rapid-onset neuroactive nasal spray currently in Phase III development for the acute treatment of anxiety in adults with social anxiety disorder (SAD). PH94B also holds potential for treating other anxiety disorders such as adjustment disorder, postpartum anxiety, PTSD, preprocedural anxiety, and panic disorders. Another key asset is PH10, a rapid-onset neuroactive nasal spray in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD). Additionally, VistaGen is developing AV-101, an oral N-methyl-D-aspartate (NMDA) receptor antagonist, in combination with oral probenecid, as a potential treatment for levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. The company collaborates with Cato Research Ltd., Pherin Pharmaceuticals, Inc., and EverInsight Therapeutics Inc. to advance its research and development efforts.
What Products and Services Does VTGN Offer?
- Develops and commercializes medicines for central nervous system (CNS) disorders.
- Focuses on treatments for anxiety, depression, and other CNS conditions.
- Utilizes rapid-onset neuroactive nasal spray technology.
- Develops oral N-methyl-D-aspartate (NMDA) receptor antagonists.
- Conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
- Collaborates with other companies to advance its research and development efforts.
- Seeks regulatory approvals for its drug candidates from agencies such as the FDA.
How Does VTGN Make Money?
- Develops drug candidates for CNS disorders.
- Outlicenses or partners for commercialization.
- Generates revenue through licensing agreements and potential future product sales.
- Focuses on clinical development and regulatory approval to increase asset value.
What Industry Does VTGN Operate In?
VistaGen operates in the competitive biotechnology industry, specifically focusing on CNS disorders. The market for CNS therapeutics is substantial, driven by the increasing prevalence of anxiety, depression, and neurodegenerative diseases. The company faces competition from established pharmaceutical companies and other biotech firms developing novel treatments for these conditions. The industry is characterized by high R&D costs, lengthy clinical trial processes, and regulatory hurdles. Success depends on demonstrating clinical efficacy and safety, securing regulatory approvals, and effectively commercializing new therapies. The company's focus on rapid-onset treatments using nasal spray technology differentiates it from some competitors.
Who Are VTGN's Key Customers?
- Pharmaceutical companies (potential partners or licensees)
- Patients suffering from anxiety, depression, and other CNS disorders
- Healthcare providers who prescribe medications for CNS disorders
F-Score 2/9Financial Health
VistaGen Therapeutics, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -17.28 places it in the distress zone, a signal of elevated financial risk.
VistaGen Therapeutics, Inc. (VTGN) Valuation Context
Valued at $7.94M, VTGN is classified as a micro-cap stock. Relative to its peer group, VTGN's quantitative score of 19/100 is below the peer average of 77/100.
Company Profile
VistaGen Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in South San Francisco, US. The company is led by CEO Shawn K. Singh. VTGN has traded publicly since 2011.
FY2026 estForward Outlook
Wall Street analysts project VistaGen Therapeutics, Inc. revenue of about $1.0M for fiscal 2026, with EPS near $-1.78. The estimate reflects 3 contributing analysts.
Net buyingInsider Activity
Over the past six months, VistaGen Therapeutics, Inc. insiders filed 9 SEC Form 4 transactions — 0 sales and 9 purchases. On net that is roughly 525K shares acquired (about $290K) — insiders putting money in tends to read as conviction.
VTGN Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2026
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future, indicating that those closest to the business believe in its potential.
- Community sentiment has turned positive, with discussions highlighting the promising results from recent clinical trials.
- Analysts note that the company is positioned to capitalize on growing interest in mental health treatments, which is a hot market.
- VistaGen's innovative approach to drug development is resonating with investors, creating a buzz around its potential breakthroughs.
Bear Case
- Concerns remain about the company's ability to secure additional funding, which could impact its ongoing projects and overall viability.
- Recent social sentiment shows some skepticism regarding the timeline for product approvals, leading to doubts about near-term growth.
- Market perception is cautious, with some investors worried about the competitive landscape in the biotech sector.
- The volatility in the biotech market has led to increased bearish sentiment, as traders weigh risks against potential rewards.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · February 2026
VTGN Latest News
-
12 Health Care Stocks Moving In Tuesday's Intraday Session
benzinga · Jun 30, 2026
-
Nasdaq Gains Over 300 Points; Chicago PMI Falls In June
benzinga · Jun 30, 2026
-
US Stocks Mixed; Home Prices Increase 1.1% In April
benzinga · Jun 30, 2026
-
VistaGen Therapeutics Q4 EPS $(0.37) Misses $(0.30) Estimate, Sales $465.000K Beat $320.000K Estimate
benzinga · Jun 15, 2026
VTGN Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for VTGN.
Price Targets
Wall Street price target analysis for VTGN.
VTGN MoonshotScore
What does this score mean?
The MoonshotScore rates VTGN's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
12 Health Care Stocks Moving In Tuesday's Intraday Session
Nasdaq Gains Over 300 Points; Chicago PMI Falls In June
US Stocks Mixed; Home Prices Increase 1.1% In April
VistaGen Therapeutics Q4 EPS $(0.37) Misses $(0.30) Estimate, Sales $465.000K Beat $320.000K Estimate
Latest VistaGen Therapeutics, Inc. Analysis
Leadership: Shawn K. Singh
CEO
Shawn K. Singh serves as the CEO of VistaGen Therapeutics, Inc. His background includes extensive experience in the biopharmaceutical industry, with a focus on corporate strategy, business development, and capital markets. He has held leadership positions at various biotech companies and has a track record of successfully raising capital and executing strategic transactions. Singh's expertise spans across multiple therapeutic areas, including CNS disorders.
Track Record: Under Shawn K. Singh's leadership, VistaGen Therapeutics has advanced its pipeline of CNS drug candidates, including PH94B, PH10, and AV-101, through various stages of clinical development. He has overseen the execution of key partnerships and collaborations, and has secured funding to support the company's research and development efforts. Singh has also focused on building a strong management team and fostering a culture of innovation within the company.
What Investors Ask About VistaGen Therapeutics, Inc. (VTGN) — Healthcare
What does VistaGen Therapeutics, Inc. do?
VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative medicines for central nervous system (CNS) disorders. Their pipeline includes PH94B, a rapid-onset neuroactive nasal spray in Phase III development for social anxiety disorder; PH10, a similar nasal spray in preparation for Phase 2B trials for major depressive disorder; and AV-101, an oral NMDA receptor antagonist being developed for multiple CNS indications. The company aims to address unmet needs in anxiety, depression, and other CNS conditions through novel therapeutic approaches.
What do analysts say about VTGN stock?
Analyst coverage of VistaGen Therapeutics, Inc. is limited, reflecting the inherent risks and uncertainties associated with clinical-stage biopharmaceutical companies. Generally, analysts focus on the potential of the company's pipeline, particularly PH94B, and the likelihood of successful clinical trial outcomes. Valuation metrics are heavily influenced by the perceived probability of success for these trials and the potential market size for the targeted indications. The company's cash runway and ability to secure additional funding are also key considerations. Analyst ratings and price targets can vary widely based on differing assumptions about these factors. No buy or sell recommendations are made here.
What are the main risks for VTGN?
The primary risks for VistaGen Therapeutics, Inc. are related to the inherent uncertainties of clinical drug development. Failure to achieve positive results in clinical trials for PH94B, PH10, or AV-101 would significantly impact the company's value. Regulatory delays or rejection of drug candidates by the FDA also pose a substantial risk. Competition from established pharmaceutical companies with greater resources and existing CNS therapies is another key challenge. Furthermore, the company's reliance on securing additional funding to support its research and development activities exposes it to financial risks, particularly if capital markets become less favorable.
What are the key factors to evaluate for VTGN?
VistaGen Therapeutics, Inc. (VTGN) holds an AI score of 19/100 (low). Not financial advice.
How frequently does VTGN data refresh on this page?
VTGN prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven VTGN's recent stock price performance?
VistaGen Therapeutics, Inc. (VTGN) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Novel drug delivery technology (nasal spray). See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider VTGN overvalued or undervalued right now?
Valuing VistaGen Therapeutics, Inc. (VTGN) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying VTGN?
Before investing in VistaGen Therapeutics, Inc. (VTGN), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- The analysis is for informational purposes only and does not constitute investment advice.
- Clinical trial outcomes are inherently uncertain.